Smith & Nephew plc SNN
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -9.48%
- 1 year
- -16.97%
- Open
- 29.87
- Prev close
- 30.41
- Mkt cap
- 12.43B
- Vol
- 1.73M
- Avg vol
- 1.46M
- EPS
- 1.47
- P/E
- 20.20
- Div yield
- 2.61%
More statistics
- Low
- 29.68
- High
- 30.12
- Forward P/E
- 12.34
- Beta
- 0.67
- Short ratio
- 3.23
- Inst. own
- 11.41%
- Dividend
- 0.79
- Ex-div date
- Oct 1, 2026
- Earnings
- Feb 23, 2027
- 50-d avg
- 28.30
- 200-d avg
- 31.08
- 1y target
- 32.32
2Y chart
Events in this range
- Oct 31, 2024Earnings: 0.5; estimate 0.8; surprise -37.5%
- Feb 25, 2025Earnings: 0.938; estimate 0.92; surprise 1.96%
- Mar 28, 2025Dividend: 0.462
- Aug 5, 2025Earnings: 0.858; estimate 0.79; surprise 8.61%
- Oct 3, 2025Dividend: 0.3
- Nov 11, 2025Rating: Canaccord Genuity · Hold → Hold
- Mar 2, 2026Earnings: 1.18; estimate 1.16; surprise 1.72%
- Mar 5, 2026Rating: Canaccord Genuity · Hold → Hold
- Mar 27, 2026Dividend: 0.482
- May 11, 2026Rating: Canaccord Genuity · Hold → Hold
- Aug 4, 2026Earnings: 0.946; estimate 0.939; surprise 0.75%
- Aug 5, 2026Downgrade: Barclays · Equal-Weight → Underweight
- Aug 6, 2026Downgrade: JP Morgan · Overweight → Neutral
- Aug 31, 2026Rating: BTIG · — → Neutral
- Oct 2, 2026Dividend: 0.312
Signals (86)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bearish | Jul 21, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| SMA: Bearish | Mar 6, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 3, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 14, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 9 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| RSI: Oversold | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 11 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| RSI: Overbought | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 5, 2025 | 1 year ago |
| RSI: Overbought | Jun 5, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| RSI: Overbought | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 11, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Jan 24, 2025 | 1 year ago |
| SMA: Bearish | Jan 23, 2025 | 1 year ago |
| SMA: Bullish | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
Key statistics
- Market cap
- 12.43B
- Enterprise value
- 67.74B
- Trailing P/E
- 20.21
- Forward P/E
- 12.34
- PEG ratio
- 1.18
- Price / sales
- 1.97
- Price / book
- 12.20
- EPS (TTM)
- 1.47
- Beta
- 0.67
- Dividend yield
- 2.61%
- Payout ratio
- 53.20%
- Profit margin
- 10.08%
- Revenue (TTM)
- 6.30B
- Revenue growth
- 4.60%
- Free cash flow
- 1.06B
- Total cash
- 754.00M
- Total debt
- 3.78B
- Return on equity
- 11.85%
- Shares outstanding
- 418.52M
- Short % of float
- 0.97%
- 50-day average
- 28.30
- 200-day average
- 31.08
Analyst view
Consensus: none
- Target (low)
- 29.00
- Target (mean)
- 32.32
- Target (high)
- 38.00
- Strong buy1
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.53.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 27, 2026 | 1.21 | — | — | — |
| Aug 4, 2026 | Jun 27, 2026 | 0.939 | 0.946 | +0.01 | +0.75% |
| Mar 2, 2026 | Dec 31, 2025 | 1.16 | 1.18 | +0.02 | +1.72% |
| Aug 5, 2025 | Jun 30, 2025 | 0.79 | 0.858 | +0.07 | +8.61% |
| Feb 25, 2025 | Dec 31, 2024 | 0.92 | 0.938 | +0.02 | +1.96% |
| Oct 31, 2024 | Jun 29, 2024 | 0.80 | 0.50 | -0.30 | -37.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2026 | BTIG | init | — | Neutral |
| Aug 6, 2026 | JP Morgan | down | Overweight | Neutral |
| Aug 5, 2026 | Barclays | down | Equal-Weight | Underweight |
| May 11, 2026 | Canaccord Genuity | main | Hold | Hold |
| Mar 5, 2026 | Canaccord Genuity | main | Hold | Hold |
| Nov 11, 2025 | Canaccord Genuity | main | Hold | Hold |
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United Kingdom
- Website
- smith-nephew.com
News
- Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
- Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
- Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
- Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell?
- MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System
- Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Your note
Sign in to keep a note on SNN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bank Of America Securities Llc | — | Holding | Jul 19, 2026 | 10,038,466 |
| BlackRock Investment Management (UK) Ltd. | — | Decrease | Nov 13, 2025 | 433,611 |
| Connolly (Paul) | — | Bought | Jul 9, 2026 | 2,833 |
| Dhankhar (Ajay) | — | Bought | Nov 5, 2025 | 18,460 |
| King (David) | — | Bought | Aug 18, 2025 | 2,800 |
| Kong (Garheng) | — | Bought | Nov 5, 2025 | 3,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| River Road Asset Management, LLC | 0.77% | 3,221,876 | 95.71M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 0.73% | 3,069,598 | 91.18M | Jun 29, 2026 |
| Brandes Investment Partners L.P. | 0.51% | 2,148,731 | 63.83M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 0.44% | 1,837,261 | 54.58M | Jun 29, 2026 |
| LMR Partners LLP | 0.42% | 1,767,872 | 52.51M | Jun 29, 2026 |
| Causeway Capital Management LLC | 0.37% | 1,565,167 | 46.49M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.08% | 333,428 | 9.90M | Aug 30, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.07% | 273,638 | 8.13M | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional International Core Equity 2 ETF | 0.07% | 297,661 | 8.84M | Jul 30, 2026 |
| American Century ETF Trust-Avantis International Equity ETF | 0.07% | 272,420 | 8.09M | Sep 29, 2026 |
| 2023 ETF Series Trust-Brandes International ETF | 0.06% | 256,404 | 7.62M | Jun 29, 2026 |
| JNL Series Trust-JNL MULTI-MANAGER SMALL CAP VALUE FUND | 0.05% | 201,147 | 5.98M | Jun 29, 2026 |